We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Super-Potent Human Antibodies Protect Against COVID-19 in Animal Tests

By HospiMedica International staff writers
Posted on 17 Jun 2020
A team of scientists at Scripps Research (La Jolla, CA, USA) have isolated powerful coronavirus-neutralizing antibodies from COVID-19 patients and successfully tested them in animals, all in less than seven weeks.

The scientists discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2 when tested in animals and human cell cultures. More...
For their project, the scientists took blood samples from patients who had recovered from mild-to-severe COVID-19. Simultaneously, the team developed test cells that express ACE2, the receptor that SARS-CoV-2 uses to get into human cells. In a set of initial experiments, the team tested whether antibody-containing blood from the patients could bind to the virus and strongly block it from infecting the test cells.

The scientists were able to isolate more than 1,000 distinct antibody-producing immune cells, called B cells, each of which produced a distinct anti-SARS-CoV-2 antibody. The team obtained the antibody gene sequences from these B cells so that they could produce the antibodies in the laboratory. By screening these antibodies individually, the team identified several that, even in tiny quantities, could block the virus in test cells, and one that could also protect hamsters against heavy viral exposure. All of this work—including the development of the cell and animal infection models, and studies to discover where the antibodies of interest bind the virus—was completed in less than seven weeks. If further safety tests in animals and clinical trials in people go well, then conceivably the antibodies could be used in clinical settings as early as next January, the researchers say.

“The discovery of these very potent antibodies represents an extremely rapid response to a totally new pathogen,” said study co-senior author Dennis Burton, PhD, the James and Jessie Minor Chair in Immunology in the Department of Immunology & Microbiology at Scripps Research.

In the course of their attempts to isolate anti-SARS-CoV-2 antibodies from the COVID-19 patients, the researchers found one that can also neutralize SARS-CoV, the related coronavirus that caused the 2002-2004 outbreak of severe acute respiratory syndrome (SARS) in Asia.

“That discovery gives us hope that we will eventually find broadly neutralizing antibodies that provide at least partial protection against all or most SARS coronaviruses, which should be useful if another one jumps to humans,” added Burton.

Related Links:
Scripps Research


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Tourniquet System
heidi– mein Tourniquet
New
Syringe Pump
SP50 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The device combines a minimally invasive, long‑lifetime “read/write” brain‑computer interface (BCI) with assistive devices and AI-driven support (photo courtesy of Epia Neuro)

Implantable Brain-Computer Interface Supports Stroke Recovery and Assistive Function

Stroke leaves many survivors with chronic motor deficits that limit independence, and cognitive decline is a growing concern in aging populations. Stroke is a leading cause of long-term disability in the... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.